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Purpose. To describe the presence of secretory leukocyte protease inhibitor (SLPI), a cationic peptide with antimicrobial and
antiprotease activity, in the innate ocular immune reaction in a rat model of Staphylococcus aureus endophthalmitis. Methods.
Seventy-ﬁve female Lewis rats were divided into three groups: the endophthalmitis group received an intravitreal injection of 65
colony-forming units of viable S. aureus, the vehicle-injected group received balanced sterile saline solution (BSS), and the control
groupwasnotinjected.Eyeswereenucleatedat24and48hoursandprocessedforimmunohistochemicalstainingandWesternblot
studies for SLPI. Results.I nS. aureus endophthalmitis eyes, there was strong immunostaining for SLPI in the retina and vitreous
with associated neutrophilic inﬁltrates. At 48 hours, corneas also stained for SLPI. Western blots conﬁrmed increased SLPI expres-
sion in all infected eyes. By immunohistochemical assays, SLPI was absent in the BSS and control eyes. The causative pathogen
was identiﬁed in all samples from the endophthalmitis group by traditional culture methods. Conclusions. To our knowledge, this
report is the ﬁrst to demonstrate the presence of SLPI in the inﬂamed cornea, vitreous, and retina tissues of rat eyes with S. aureus
endophthalmitis, suggesting that SLPI has an active role in the innate immunity of the eye. Release of SLPI by inﬂammatory cells
in the anterior and posterior segments may contribute to the host defense response against infectious endophthalmitis.
Copyright © 2007 Victor E. Reviglio et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Infectious endophthalmitis is a potentially devastating com-
plication of intraocular surgery, most commonly cataract
extraction [1, 2]. Within hours, tissue damage and conse-
quentlossofvisionresultfromtheinﬂammatoryprocess[2].
StaphylococcusepidermidisandStaphylococcusaureushavere-
mained the most prevalent infectious agents in postoperative
bacterial endophthalmitis [3]. Early diagnosis and prompt
treatment are essential to allay the host inﬂammatory re-
sponse [1]. Speciﬁc and nonspeciﬁc defense mechanisms
play an important role in ocular immunity, maintaining a
delicate balance between eﬀective defenses and potentially
harmful inﬂammation responses [4]. Antimicrobial peptides
contribute to innate immune defense against a number of
GrampositiveandGramnegativebacteria,viruses,andfungi
[5]. These peptides include secretory leukocyte protease in-
hibitor (SLPI) [6–8], a cationic peptide, as well as defensins
and cathelicidins.
Human SLPI is an 11.7kDa nonglycosylated protein ini-
tially isolated from respiratory mucosal epithelial cells [8].
It is composed of two domains: a protease inhibitor at
the carboxyl-terminal domain and the antimicrobial amino-
terminal domain [8–10]. SLPI has defensin-like antibacte-
rial activities and suppresses the production of inﬂammatory
mediators [9]. Recent studies demonstrate that macrophages
secrete SLPI in response to bacterial lipopolysaccharides and
toxins; therefore, we assume that SLPI modulates the ocular
immune response in endophthalmitis [11, 12].
To determine whether SLPI has a role in inﬂammation
and infection of the eye, where SLPI has not been described
before, we investigated and quantiﬁed SLPI expression in2 Mediators of Inﬂammation
normal and infected ocular tissues using a murine bacterial
endophthalmitis model.
2. MATERIALS AND METHODS
2.1. Experimentaldesign
Animals were handled in compliance with the tenets of
the Association for Research in Vision and Ophthalmology
(ARVO) statement for the use of animals in Ophthalmic and
Vision Research and the Guide for the Care and Use of Labo-
ratoryAnimals(NationalResearchCouncil).Allexperiments
were approved by the Institutional Animal Care Committee
of the Catholic University of Cordoba, Argentina.
Seventy-ﬁve female Lewis rats, each weighing 250g, were
divided amongst three groups: (1) the S. aureus inoculated
group (30 rats), (2) the vehicle-injected group (30 rats), and
(3) the un-injected control group (10 rats). The right eye of
the S. aureus and the vehicle-injected rats received intravit-
real injections of S. aureus inoculum and balanced salt solu-
tion (BSS), respectively; the left eye was uninjected. The rats
were divided as follows: of the 30 rats in the S. aureus group,
8 rats were assigned to immunohistochemistry at 24 hours,
7r a t st oW e s t e r nb l o t t i n ga t2 4h o u r s ,8r a t st oi m m u n o h i s -
tochemistry at 48 hours, and 7 rats to Western blotting at 48
hours. The same was done with the 30 rats in the vehicle-
injected group. The 10 rats without injection were divided
into 5 rats for immunohistochemistry and 5 rats for Western
blotting.
S.aureusfromahumanendophthalmitissamplewascul-
tured in tryptase soy broth. The bacterial suspension was
centrifuged, and washed with sterile saline. The suspen-
sion was serially diluted with sterile saline to 65CFU/50μL.
Each rat was anesthetized with an intramuscular injection
of 0.125ml of a 1 : 1 mixture of 100mg/ml ketamine and
20mg/ml xylazine; a drop of proparacaine 0.5% was instilled
in the right eye of S. aureus inoculated and sham injected
rats.FiveμLofaqueoushumorwasaspiratedfromtheexper-
imentaleyestominimizeanyincreaseinintraocularpressure
with the subsequent inoculation of S. aureus or BSS. The ex-
perimental S. aureus group received an intravitreal injection
of 50μL( 6 5C F U )o fS. aureus suspension through the pars
plana, and the vehicle-injected group received 50μL of BSS.
Postinjection eyes were irrigated with BSS. Rats were euth-
anized using phenobarbital at 24 or 48 hours after the in-
jection, and eyes were harvested for immunohistochemical
studies.
2.2. Fixationandprocessingoftissuefor
immunohistochemistry
The right eyes from the S. aureus inoculated (eight rats for
each time point), vehicle-injected groups (eight rats for each
time point), and untreated control (5 rats) groups eutha-
nized at 24 and 48 hours were enucleated for immunohisto-
chemical studies. The eyes were submerged in 10% buﬀered
formalin for 3 days, washed with distilled water, rehydrated
through a graded series of ethanol, embedded in paraﬃn,
and processed for immunohistochemistry.
Immunohistochemical staining was performed using
an avidin-biotin-peroxidase complex technique. Paraﬃn-
embedded sections were treated with 0.6% hydrogen perox-
ide in methanol and blocked with 10% normal goat serum.
Primary antibody consisted of 1 : 100 dilution of polyclonal
goat anti-SLPI at 1 : 100 dilution (Santa Cruz Biotechnol-
ogy, Inc., Santa Cruz, Calif, USA) was applied to the eye
sections, incubated at room temperature for 1 hour, and
the unbound antibody was removed with TBS (20mM Tris-
HCl pH 7.5, 150mM NaCl). A biotinylated rabbit anti-goat
IgG secondary antibody (Vector Laboratories, Burlingame,
Calif, USA) was applied and ampliﬁed with avidin-biotin-
peroxidase complex (Vector Laboratories, Burlingame, Calif,
USA). Signals were developed for visualization with 3,3  di-
aminobenzidine. Control sections were incubated with nor-
mal goat serum. All samples were stained in parallel to mini-
mizespecimenvariation.Maskedpathologistsgradedthecell
staining intensity quantitatively.
2.3. Westernblotanalysis
Vitreous samples were collected from the right eyes of seven
rats from the S. aureus inoculated group, seven rats from the
vehicle-injected group, and 5 rats from the control group us-
ing a 20-gauge needle. Retina tissue was excised under a dis-
secting microscope by masked pathologist and placed in a
sterile tube. Vitreous samples and retina tissue were homog-
enized separately in phosphate-buﬀered saline with 100μM
butylated-hydroxytoluene and centrifuged for 10 minutes at
15400g. The supernatants were stored at −80◦C.
The levels of SLPI from vitreous and retinal samples were
assessed by Western blot, with each blot being performed
in duplicate. The blot was probed with polyclonal antibody
against SLPI used for the immunostaining. For the posi-
tive control we used serum from rats with S. aureus sepsis
(data not shown). Fifteen microliters of each homogenate
were run under either reducing or nonreducing (r, nr) con-
ditions at ambient temperature using a modiﬁed Laemmli
method.Thesampleswereelectrophoresedon10–15%poly-
acrylamideSDSgelat100voltsfor2hoursandtransferredto
nitrocellulose membranes at 120 volts for 2 hours (Bio-Rad,
Richmond, Calif, USA). The nitrocellulose paper was incu-
bated at room temperature in blocking buﬀer (PBS, 0.05%
Tween 20, 0.5% nonfat dry milk) with the primary anti-
body (1 : 1000 dilution) and the secondary antibody (1 :
2000 dilution) for 1 hour each on a rotating platform. After
three washes with TBS-T (TBS, 0.05% Tween-20), the mem-
branes were incubated in enhanced chemiluminescence so-
lution (Amersham Life Science, Arlington Heights, Ill, USA)
followed by exposure to ﬁlm.
The Western blots from ocular specimens with each one
in duplicate were subjected to densitometry analysis (Molec-
ular Dynamics, Sunnyvale, Calif, USA) and normalized to a
standard curve to obtain relative SLPI values.
2.4. Statisticalanalysis
Relative SLPI values were reported as mean ± standard de-
viation (SD). Statistical analysis comparing the S. aureusVictor E. Reviglio et al. 3
Table 1: Immunohistochemical detection of secretory leukocyte protease inhibitor in ocular rat samples.
24h 48h
Experimental group Endoph. BSS Endoph. BSS
Cornea OD 2/8 0/8 6/8∗∗ 0/8
OS 0/8 0/8 0/8 0/8
Vitreous OD 8/8∗∗ 0/8 8/8∗∗ 0/8
OS 0/8 0/8 0/8 0/8
Retina OD 8/8∗∗ 0/8 8/8∗∗ 0/8
OS 0/8 0/8 0/8 0/8
∗ Double masked observer determined the total positive immunostained corneas for SLPI in the experimental group. Immunoreactivity is reported as num-
ber of positively immunostained eyes/total number of eyes examined in the endophthalmitis group at 24 and 48 hours.
∗∗Statistically diﬀerent when comparing the Staphylococcus aureus or BSS inoculated eye (OD) to normal control eye (OS). (P < .05 using Fisher’s exact test
analysis.) ns = not statistically signiﬁcant.
(a) (b) (c)
(d) (e) (f)
Figure 1: Photomicrographs of immunostaining for SLPI at 24 hours in the endophthalmitis group (panels a-b). Note positive retinal SLPI
immunostaining,associatedwithinﬂammatorycellinﬁltrationandtissuenecrosis.Nostainingwaspresentinvitreousandretinalstructures
in the normal and BSS groups (panels c-d). Strong expression of SLPI was identiﬁed in endophthalmitis samples at 48 hours at vitreous
samples as well as corneal tissue (arrows, panels e-f). (Immunohistochemistry, ×800, panels a-b-e, and ×400 magniﬁcation panels c-d-f.)
inoculated, vehicle-injected, and control groups was done
using the Mann-Whitney test. A P value less than .05 was
considered statistically signiﬁcant.
3. RESULTS
We used a murine model to elucidate the role of SLPI,
an antimicrobial peptide, in endophthalmitis. Immuno-
histochemical studies show an initial neutrophilic inﬁl-
trate consistent with the inﬂammatory response evident at
histopathology examination. At 24 hours after intraocular
inoculation with S. aureus, there was intense SLPI staining in
the vitreous and retinal tissues (Figures 1(a) and 1(b)). The
eyes from the vehicle-injected and untreated control groups
did not show clinical signs of inﬂammation, inﬂammatory
cell inﬁltrates, or SLPI staining in the vitreous and retina by
immunohistochemistry (Figures 1(c) and 1(d)). A few sam-
ples (n = 3) from the vehicle-injected and control groups
showed weak SLPI staining of retinal vessels (not shown).
At 24 hours postinoculation, the anterior segment struc-
tures did not manifest histological or immunohistochemical
changes.
Forty-eight hours post inoculation, eyes from the S. au-
reus inoculated group demonstrated an intense inﬂamma-
tory reaction at slit lamp examination. In contrast with the
eyes 24 hours postinoculation, there was evident inﬂamma-
tionoftheanteriorsegment.Theinﬂammatoryinﬁltratewas
more marked with associated tissue necrosis. Immunohisto-
chemically, there was intense and diﬀuse staining of SLPI in
all ocular structures. Positive staining for SLPI in the ante-
rior chamber, corneal epithelium, and stroma corroborated
the slit lamp ﬁndings of keratitis (Figures 1(e) and 1(f)).4 Mediators of Inﬂammation
Table 2: Western blot densitometry analysis of secretory leukocyte protease Inhibitor in ocular rat samples.
24h 48h
Experimental group Endoph. BSS Endoph. BSS
Vitreous OD 179.37 ± 3.92∗∗ 0.25 ± 0.15 191.66 ± 4.12∗∗ 0.15 ± 0.17
OS 0.10 ± 0.28 0.10 ± 0.06 0.23 ± 0.09 0.08 ± 1.14
Retina OD 195.77 ± 3.26∗∗ 10.14 ± 3.04 199.29 ± 1.95∗∗ 13.71 ± 2.20
OS 11.22 ± 2.94 8.72 ± 1.61 11.31 ± 0.11 10.94 ± 1.10
∗ Double masked observer determined the total positive immunoblots for SLPI in the posterior segment eye structures. The immunoblots for SLPI from en-
dophthalmitis and BSS groups were subjected to densitometry analysis.
∗∗Statistically diﬀerent when comparing the Staphylococcus aureus or BSS inoculated eye (OD) to normal control eye (OS). P < .05 using Mann-Whitney test;
values are means +/− standard deviation. ns = not statistically signiﬁcant.
123 M W 4 56
(a)
123 M W 4 56
(b)
M W 12 345
(c)
123 M W 4 5 6
(d)
Figure 2: Representative western blots of SLPI expression of supernatant from the endophthalmitis group (a)-(b) and BSS group (c)-(d)
were analyzed. Infection with associated inﬂammation induces the expression of SLPI (12kDa) at 48 hours in vitreous (a) and retina (b)
homogenates in all infected eyes. There is no expression at 48 hours in vitreous samples from injected BSS group (c). However, a weak
basal expression at retinal homogenates was found in BSS and control groups (d). Note the strong level of SLPI in the endophthalmitis
g r o u p( a ) ,( b ) .
Eyes in the vehicle-injected and control groups did not
reveal inﬂammatory changes at slit lamp examination or in
histopathologystudies.WhenexaminedforpresenceofSLPI,
none of eyesstudied hadany discernible immunohistochem-
ical reaction.
S. aureus infection with its associated inﬂammatory re-
sponse is a major trigger for the increased production of
SLPI, not observed in the vehicle-injected or untreated con-
trol groups at 24 or 48 hours (Table 1).
We used Western blots with densitometry to quantify
SLPI protein expression in the posterior segment structures.
Both the vitreous and retinal homogenates from the S. au-
reus inoculated group at either 24 or 48 hours post injection
had high levels of SLPI speciﬁc immunoreactivity by West-
ern blot (Figures 2(a) and 2(b)). The vehicle-injected and
untreated control groups were void of SLPI expression in
the vitreous at both time points (Figure 2(c)). In contrast,
retinal homogenates from the vehicle-injected and untreated
rats showed slight SLPI expression both at 24 or 48 hours
postinjection (Figure 2(d)).
The values of SLPI bands from western blots were quan-
tiﬁed by densitometric analysis and subjected to statistical
analysis (P < .05 versus control group, Mann-Whitney test)
to determine whether there was a diﬀerence between the en-
dophthalmitis group and the BSS groups (Table 2).
4. DISCUSSION
We hypothesized that SLPI plays a role in the innate immune
defense of the eye in response to intraocular inﬂammation
and infection. This study is the ﬁrst to document that SLPI
is strongly expressed in inﬂamed eyes in an animal model of
endophthalmitis and that SLPI expression is directly associ-
ated with inﬁltration by inﬂammatory cells in ocular tissues.
Given what is known about the role of SLPI in other tissues
such as lung, skin, and placenta [8, 22, 26], our ﬁndings sug-
gest that SLPI is secreted in order to promote the early erad-
ication of invading microorganisms and to protect the eye
against proteolytic destruction by inﬂammatory cells.
We conclude that SLPI expression increases as a result
of S. aureus infection and the associated inﬂammatory re-
sponse. This is supported by our ﬁndings that SLPI expres-
sion correlates in location, time, and intensity with the clini-
calinfection.SLPIexpressionandtheinﬂammatoryresponse
colocalize in the posterior segment in inoculated eyes. As
the infection progresses to the anterior segment at 48 hours,
the SLPI immunoreactivity colocalizes to the cornea. By im-
munohistochemistry,SLPIisupregulatedasthemountedin-
ﬂammatory response intensiﬁes at 48 hours when compared
to the 24-hour time point. Thus, SLPI expression also corre-
lates temporally and in intensity with the infectious process.Victor E. Reviglio et al. 5
The absence of elevated SLPI expression in the sham-
injected eyes argues against the trauma from the injection
as the cause of the SLPI response. The correlation of SLPI
in place, time, and intensity with the inﬂammatory process
strongly supports that SLPI is upregulated as a result of the
infection and/or inﬂammation. The weak expression of SLPI
inretinalhomogenatesfromcontrolandBSSgroupsinWest-
ern blots may be associated with the retinal vessels that stain
for SLPI in immunohistochemistry assays and not be related
to production by native retinal cells. The presence of SLPI in
the retinal vasculature suggests that SLPI is produced by cells
recruited from the extracellular matrix (ECM).
Several microbiological studies describe that the most
common pathogens responsible for acute postoperative en-
dophthalmitis are Staphylococcus species, the rationale un-
derlying the choice of a clinical isolate of S. aureus for our
study [1, 3]. The consequences of endophthalmitis are dire:
delayed diagnosis and treatment of endophthalmitis may
produce irreversible inﬂammatory damage and may con-
sequently lead to loss of vision [1, 4, 13]. The inﬂamma-
tory chemotactic factors and toxins from bacteria can in-
duce leukocyte inﬁltration, principally transendothelial mi-
gration of neutrophils from the vascular circulation to the
ECM [14]. The ECM serves as a structural scaﬀold of macro-
moleculesandasareservoirofinﬂammatorymediators[15].
The balance between ECM formation and destruction asso-
ciated with inﬂammatory and infectious processes is main-
tained by the presence of endogenous tissue inhibitors of
proteases [16, 17].
The concept that certain peptides have antiinﬂammatory
properties and contribute to the innate host defense has been
reported in other organ systems [18]. Speciﬁcally, SLPI is in-
volved in protection against damage from tissue inﬂamma-
tion [9, 12]. It also neutralizes the action of neutrophil elas-
tase as well as other proteases secreted in the ECM [19, 22].
In addition, SLPI is upregulated in response to proinﬂam-
matory cytokines, such as IL-1 and TNF-α,a n dt ob a c t e -
rial products [9, 11]. Recent studies demonstrate that the
SLPI is secreted by inﬂammatory and noninﬂammatory cells
in response to tissue destruction [8, 9, 12, 23–26]. In con-
junction with our ﬁndings, SLPI likely plays a similarly im-
portant pathophysiologic role in bacterial endophthalmitis,
Most likely, it is expressed in response to inﬂammation itself,
although our data do not directly rule out SLPI expression
directly triggered by bacterial toxins or cell wall components.
In conclusion, we demonstrate that SLPI is not produced
in ocular tissues under normal physiologic conditions. This
peptide may be secreted in order to promote the early erad-
ication of invading microorganisms and to protect the eye
against proteolytic destruction by inﬂammatory cells. Previ-
ous experiments shows SLPI expression in bronchial, nasal,
and cervical tissues and in tears [19–21]; our study expands
upon these ﬁndings and highlights the role of SLPI in in-
traocular inﬂammation and ocular innate immunity. The
known antiprotease and antimicrobial activities of SLPI sug-
gest that its expression is actively regulated at the site of
ocular tissue inﬂammation. Because of its endogenous an-
timicrobial activities and role as an inﬂammatory mediator,
further studies addressing the role of SLPI in innate ocular
immunity and in wound healing may have consequences in
the development of innovative prophylactic and therapeutic
strategies for eye disease.
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